Last $9.29 USD
Change Today +0.22 / 2.43%
Volume 959.6K
HALO On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

halozyme therapeutics inc (HALO) Snapshot

Open
$9.15
Previous Close
$9.07
Day High
$9.35
Day Low
$9.08
52 Week High
01/24/14 - $18.18
52 Week Low
08/8/13 - $6.51
Market Cap
1.2B
Average Volume 10 Days
1.3M
EPS TTM
$-0.78
Shares Outstanding
124.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for HALOZYME THERAPEUTICS INC (HALO)

halozyme therapeutics inc (HALO) Related Businessweek News

No Related Businessweek News Found

halozyme therapeutics inc (HALO) Details

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes human enzymes. Its research focuses on human enzymes that transiently modify tissue under the skin to facilitate the delivery of injected drugs and fluids, or to alter abnormal tissue structures for clinical benefit. The company’s products are based on the Enhanze technology, a patented human recombinant hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to increase the dispersion and absorption of other injected drugs; in subcutaneous urography; and to improve resorption of radiopaque agents. The company is also developing Ultrafast Insulin program, a Phase II clinical trial product for the treatment of type 1 and 2 diabetes mellitus; PEGPH20, a new molecular entity that is in Phase II clinical trial for the treatment of pancreatic cancer; and HTI-501, a lysosomal proteinase, which is in Phase 1/2 clinical trial for the treatment of edematous fibrosclerotic panniculopathy. It has collaborative partnerships with F. Hoffmann-La Roche, Ltd and Hoffmann-La Roche, Inc.; Pfizer Inc.; and Baxter Healthcare Corporation. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

170 Employees
Last Reported Date: 02/28/14
Founded in 1998

halozyme therapeutics inc (HALO) Top Compensated Officers

Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $314.9K
Vice President, General Counsel and Secretary
Total Annual Compensation: $317.5K
Consultant
Total Annual Compensation: $366.7K
Compensation as of Fiscal Year 2013.

halozyme therapeutics inc (HALO) Key Developments

Halozyme Therapeutics, Inc. Resumes Patient Enrollment and Dosing In PEGPH20 Clinical Program in Pancreatic Cancer

Halozyme Therapeutics, Inc. announced that it has resumed enrollment and dosing of patients in its ongoing Phase 2 trial (Study 202) evaluating PEGPH20 in patients with pancreatic cancer under the revised clinical protocol agreed to with the FDA in June. PEGPH20 is an investigational PEGylated form of Halozyme's proprietary recombinant human hyaluronidase under development for the systemic treatment of tumors that accumulate hyaluronan. Study 202 (Halo 109-202) is a Phase 2 multicenter, randomized clinical trial evaluating PEGPH20 as a first-line therapy for treatment of patients with stage 4 metastatic pancreatic cancer. The primary outcome of the trial is to measure improvement in progression-free survival in patients receiving PEGPH20 in combination with gemcitabine and nab-paclitaxel compared to gemcitabine and nab-paclitaxel alone. A second primary endpoint will assess the thromboembolic event rate in the PEGPH20 treatment arm. Secondary endpoints also include objective response rate and overall survival.

Halozyme Therapeutics, Inc. to Resume PEGPH20 Clinical Program in Pancreatic Cancer

Halozyme Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on patient enrollment and dosing of PEGPH20 in the ongoing Phase 2 trial (Study 202) evaluating PEGPH20 in patients with pancreatic cancer permitting the study to resume under a revised protocol. Patient enrollment is anticipated to recommence upon review and approval of the amended protocol by the Independent Review Boards at the participating clinical trial sites. In May, the trial's independent Data Monitoring Committee (DMC) recommended that enrollment and dosing in the study resume under a revised protocol. Study 202 (Halo 109-202) is a Phase 2 multicenter, randomized clinical trial evaluating PEGPH20 as a first-line therapy for treatment of patients with stage IV metastatic pancreatic cancer. The primary outcome of the trial is to measure improvement in progression-free survival in patients receiving PEGPH20 in combination with gemcitabine and nab-paclitaxel compared to gemcitabine and nab-paclitaxel alone. A second primary endpoint has been added to assess the thromboembolic event rate in the PEGPH20 treatment arm following the protocol amendment. Secondary endpoints include objective response rate and overall survival. The protocol amendments to the study include the exclusion of patients who may be at higher risk of thromboembolic events. Additionally, low-molecular weight heparin will be used as a prophylaxis to prevent thromboembolic events. In addition to the over 100 patients already enrolled in the trial, Halozyme plans to enroll a similar number of additional patients. PEGPH20 is an investigational PEGylated form of Halozyme's proprietary recombinant human hyaluronidase under development for the systemic treatment of tumors that accumulate hyaluronan.

Halozyme Therapeutics, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-05-2014 12:30 PM

Halozyme Therapeutics, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-05-2014 12:30 PM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Helen I. Torley, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HALO:US $9.29 USD +0.22

HALO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amphastar Pharmaceuticals Inc $9.14 USD -0.36
View Industry Companies
 

Industry Analysis

HALO

Industry Average

Valuation HALO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 19.6x
Price/Book 16.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 16.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HALOZYME THERAPEUTICS INC, please visit www.halozyme.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.